

Anti-TNFRSF8/CD30 Antibody (Brentuximab vedotin)

Introduction

Brentuximab vedotin solution is a solution form of Brentuximab vedotin. Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) containing an anti-CD30 antibody and the cytotoxic agent monomethyl auristatin E (MMAE).

Product parameters

Alternative Names	Adcetris, SGN-35, cAC10-vcMMAE
Target Accession	P28908
Target	TNFRSF8 / CD30
CAS number	914088-09-8
Molecular Weight	145.48 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	MMAE is conjugated by sulfhydryl coupling, the DAR value of Anti-TNFRSF8/CD30 Antibody (Brentuximab vedotin) antibody is 4.0.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

